184 related articles for article (PubMed ID: 20950790)
1. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
Baumgart J; Nilsson K; Stavreus-Evers A; Kask K; Villman K; Lindman H; Kallak T; Sundström-Poromaa I
Am J Obstet Gynecol; 2011 Jan; 204(1):26.e1-7. PubMed ID: 20950790
[TBL] [Abstract][Full Text] [Related]
2. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
[TBL] [Abstract][Full Text] [Related]
3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
[TBL] [Abstract][Full Text] [Related]
5. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
7. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
11. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
Baumgart J; Nilsson K; Evers AS; Kallak TK; Poromaa IS
Menopause; 2013 Feb; 20(2):162-8. PubMed ID: 22990756
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
Chahine G; Howayek M; Atallah D
J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
[TBL] [Abstract][Full Text] [Related]
14. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
16. Amenorrhoea, menopause, and endocrine therapy for breast cancer.
Amir E; Seruga B; Freedman O; Clemons M
BMJ; 2009 Dec; 339():b4261. PubMed ID: 19959583
[No Abstract] [Full Text] [Related]
17. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer.
Chin SN; Trinkaus M; Simmons C; Flynn C; Dranitsaris G; Bolivar R; Clemons M
Clin Breast Cancer; 2009 May; 9(2):108-17. PubMed ID: 19433392
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD; Goss PE
Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
